A5024073023- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Histiocytic Disorders and Treatments
- Effects of Radiation Exposure
- Immune Cell Function and Interaction
- Genetic and rare skin diseases.
- Genital Health and Disease
- Multiple and Secondary Primary Cancers
- Parvovirus B19 Infection Studies
- Palliative Care and End-of-Life Issues
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Diagnosis and Treatment
- Advanced Biosensing Techniques and Applications
- Prenatal Screening and Diagnostics
- Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cancer Risks and Factors
- Polyomavirus and related diseases
- CNS Lymphoma Diagnosis and Treatment
- Iron Metabolism and Disorders
- Ectopic Pregnancy Diagnosis and Management
- Assisted Reproductive Technology and Twin Pregnancy
Michigan United
2025
Texas Children's Hospital
2017-2024
Children's Cancer Center
2020-2024
Baylor College of Medicine
2017-2024
C. S. Mott Children's Hospital
2023-2024
University of Michigan–Ann Arbor
2023-2024
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by pathologic immune activation in which prompt recognition and initiation of suppression essential for survival. Children with HLH have many overlapping clinical features critically ill children sepsis systemic inflammatory response (SIRS) whom alternative therapies are indicated. To determine whether plasma biomarkers could differentiate from other conditions to better define core signature HLH, concentrations proteins...
Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and Anaplastic Lymphoma Kinase (ALK) inhibitors. However, there is no standard treatment limited published data evaluating their use. The goal this retrospective study to describe current real-world outcomes pediatric, adolescent, young adult R/R ALK-positive ALCL. We conducted a retrospective,...
Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary dysfunction. Current follow-up care guidelines discordant. Therefore, the International Late Effects Childhood Cancer Guideline Harmonization Group established convened a panel 33 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence regarding factors for dysfunction, types function testing, timings surveillance, then we formulated our recommendations....
Summary Optimal therapeutic approaches for advanced Langerhans cell histiocytosis (LCH) are not known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway inhibition in 10 patients refractory systemic disease and/or LCH‐associated neurodegeneration. Overall response rate was 9/10 (90%) entire cohort: 5/5 (100%) 6/7 (86%) central nervous system disease. BRAF V600E+ peripheral blood fraction decreased 5/6 (83%). Toxicities included fever, skin rash, myalgias,...
Background Curative therapy places childhood cancer survivors at increased risk for second primary malignancies (SPMs). However, there have been few population‐based attempts to characterize differences between outcomes of SPMs in and first (FPMs). Methods Clinical demographic information about who developed individuals with comparable FPMs was extracted from the Surveillance, Epidemiology, End Results program. Hazard ratios (HRs) 95% confidence intervals (CIs) were estimated Cox...
Summary Over 50% of patients with systemic LCH are not cured front‐line therapies, and data to guide salvage options limited. We describe 58 who were treated clofarabine. Clofarabine monotherapy was active against in this cohort, including heavily pretreated a objective response rate 92.6%, higher children (93.8%) than adults (83.3%). BRAF V600E+ variant allele frequency peripheral blood is correlated clinical responses. Prospective multicentre trials warranted determine optimal dosing,...
Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed–Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected the levels cytokines or chemokines pre-therapy plasma children with HL. The study objectives were to better define proteome and identify biomarkers associated extent disease clinical outcomes Pre-therapy samples obtained from subjects newly diagnosed healthy controls....
We present 2 diagnostically challenging cases of pediatric/adolescent relapsed/refractory aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) within the spectrum Burkitt and diffuse large illustrate different therapeutic regimens that are employed for pediatric adult cancer centers. Both displayed varying-sized cells with occasional single prominent nucleoli heterogeneous BCL2 expression. Cytogenetics revealed complex karyotypes t(8:14)(q24.2;q32) IGH::MYC rearrangement by FISH. Next...
Abstract Telomere biology disorders predispose affected individuals to specific malignancies and organ fibrosis in tissues sensitive telomere length (TL) shortening, especially after exposure chemotherapy radiation. We report a case of 17‐year‐old female with Hodgkin lymphoma who developed severe chemotherapy‐related toxicities. She was subsequently found have peripheral blood lymphocyte TL < 1st percentile pathogenic variant TERT inherited from her father. This demonstrates that early...
ABSTRACT Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary dysfunction. Current follow-up care guidelines discordant. Therefore, the International Late Effects Childhood Cancer Guideline Harmonization Group established convened a panel 33 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence regarding factors for dysfunction, types function testing, timings surveillance, then we formulated our...
112 Background: Survivors of Hodgkin lymphoma (HL) are at risk for pulmonary late effects, including fibrosis (PF). Established factors such as younger age diagnosis and specific therapeutic exposures explain a fraction the these outcomes. Notably, systemic inflammation impaired telomere maintenance associated with adverse outcomes in adult populations, but have not been explored cancer survivors. Our aim was to identify diffusion defects HL survivors, evaluate impact short lymphocyte length...
Background: Curative therapy places childhood cancer survivors at increased risk of second primary malignancies (SPMs). However, there have been few population-based attempts to characterize differences in outcomes between SPMs and comparable de novo first (FPMs).Methods: We extracted clinical demographic information from who developed individuals with FPMs using the Surveillance, Epidemiology, End Results (SEER) 1973-2015 database. Hazard ratios (HR) 95% confidence intervals (CI) were...